Atea Pharmaceuticals (AVIR) Q3 2024 earnings summary

Executive summary

• Significant progress in the HCV program with bemnifosbuvir and ruzasvir, advancing to Phase 2 with strong efficacy and safety; topline results expected early December 2024 and Phase 3 initiation planned for early 2025.

• COVID-19 program discontinued after the Phase 3 SUNRISE-3 trial failed to meet primary endpoints due to evolving disease dynamics and milder cases.

• $482.8 million in cash, cash equivalents, and marketable securities as of September 30, 2024, expected to fund operations through 2027.

• No product revenue to date; continued operating losses expected as pipeline advances.

Financial highlights

• Net loss for Q3 2024 was $31.2 million, compared to $33.1 million in Q3 2023; net loss for the nine months ended September 30, 2024 was $134.8 million, up from $96.8 million year-over-year.

• Research and development expenses decreased year-over-year, mainly due to lower COVID-19 spending, partially offset by higher HCV trial costs.

• General and administrative expenses declined to $11.0 million in Q3 2024, mainly from reduced professional fees.

• Interest income fell due to lower investment balances.

• Cash, cash equivalents, and marketable securities decreased to $482.8 million from $578.1 million at year-end 2023.

Outlook and guidance

• Cash runway projected through 2027, supporting completion of the HCV Phase 3 program and ongoing clinical development.

• Topline Phase 2 SVR12 results for HCV combination expected in early December 2024; End of Phase 2 FDA meeting planned for early Q1 2025 to support Phase 3 initiation.

• R&D spending for the remainder of 2024 will focus on HCV Phase 2 completion and Phase 3 startup activities.

• Ongoing early-stage discovery for protease inhibitors targeting respiratory and other ssRNA virus diseases.